跳至主要内容
临床试验/PER-032-99
PER-032-99已完成未知

A Multicenter Comparative Study of Cefepime Versus Broad-Spectrum Antibacterial Therapy in Moderate and Severe Bacterial Infections

BRISTOL MYERS SQUIBB PERÚ S.A.,0 个研究点目标入组 0 人开始时间: 1999年5月13日最近更新:

试验速览

阶段
未知
状态
已完成

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Age 18 years or older;
  • The subject or their legally authorized representative who has given their informed consent to participate in the study.
  • All women with the potential to conceive should have a documented pregnancy test in serum or urine, with a negative result and a minimum sensitivity of 25 IU / 1 human chorionic gonadotropin (BHCG), obtained within 48 hours prior to start of study drug administration (see Appendix I); Women with potential to conceive (MCPC) are those who have experienced menarche and have not undergone surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or are not in postmenopause [defined as amenorrhea for 12 consecutive months or more ; women who are receiving hormone replacement therapy (TSH) with a documented plasma level of follicle-stimulating hormone (FSH)> 35 mlUl / ml]. Women who are using oral contraceptive, implant or injectable hormones or mechanical products such as intrauterine device or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy; who practice abstinence or whose partner is sterile (for example, vasectomy) will be considered as women with potential to conceive.
  • Patients requiring hospitalization or patients who have been hospitalized for less than 3 days;
  • Patients with a score of> 5 and <19 in the APACHE II classification system
  • The diagnosis of pneumonia requires clinical evidence of pneumonia verified by the presence of a new infiltrate or infiltrates on the chest radiograph and two or more of the following characteristics:
  • -fever (> 38 ° C or I00.4 ^ F)
  • -leukocytosis (> 10,000 leukocytes / mm ^ or> 15% in bands)
  • purulent sputum (> 25 PMN and <10 squamous epithelial cells per low power field)
  • - chest pain
  • - abnormal auscultatory findings, such as rales or egophony
  • - headache
  • - general discomfort
  • Infection of the urinary tract
  • The diagnosis of urinary tract infection requires the isolation of> 10 leukocytes / hpf obtained from centrifuged urine collected by the sterile collection technique or by catheterization, and two of the following conditions:
  • -Fever (> 38.0 ° C or 100.4 ° F);
  • -Leukocytosis (> 10,000 leukocytes / mm ^ or> 15% in bands);
  • - Symptoms of the upper tract (pain in the side or back or abnormal sensitivity of the costovertebral angle).
  • The history of recurrent urinary tract infections and known urological complications (such as kidney stones, obstruction, neurogenic bladder, prostatic hypertrophy) should be recorded in the case report form.
  • Clinical evidence of sepsis verified by;
  • Fever (> 38.0 ° C or 100.4 ° F) or hypothermia (<36.0 ° C);
  • Tachycardia> 90 Ipm;
  • Leukocytosis (> 12,000 leukocytes / nim ^ o> 10% band forms) or leukopenia (<4,000 leukocytes / mm ^);
  • Respiratory frequency> 20;
  • PAC02 <32 mmHg
  • Evidence or suspicion of infection elsewhere, and at least one of the following characteristics:
  • - Hypotension (reduction of systolic and diastolic pressures by 20 mmHg
  • and 10 mmHg, respectively, below the baseline value of the patient for at least 8 hours in the absence of another evident cause in addition to sepsis);
  • - Oliguria (<15 ml / hr of urine for 4 hours);
  • -Hyperventilation (respiratory rate> 25 Ipm, or an increase of 15 Ipm, above the baseline value of the patient during 4 hours, in

排除标准

  • Pregnancy and / or lactation;
  • Patients with scores of <5 or> 19 in the Apache II classification system
  • A life expectancy of less than 3 days or patients who have been placed in a no resuscitate state;
  • History of type I reaction or anaphylactic reaction to penicillins and
  • / or to any of the study drugs (Cephalosporins of 1, 2, 3 or 4 ^ generation, aminoglycosides, macrolides, metronidazole and vancomycin).
  • Current, clinically significant liver disease (ie, ALT and / or
  • AST and / or total bilirubin> 5 times the normal maximum limit);
  • Chronic renal failure (such as, for example, patients with a serum creatinine level> 3.0 mg / dl or who require renal dialysis);
  • Patients requiring intubation for respiratory support (except for patients who require intubation for the administration of surgical anesthesia);
  • Any other condition or therapy that, in the opinion of the Investigator or as indicated on the product label, could entail a risk to the patient or interfere with the objectives of the study;
  • Administration of any other investigational medication within 30 days prior to the start of treatment, and participation in other clinical studies at the same time as in this protocol;
  • Any other condition for which, in the opinion of the investigator, the patient is not eligible to be admitted to the study.

研究者

相似试验

A Multicenter Comparative Study of Cefepime Versus... | 临床试验